Literature DB >> 30190915

The role for chemotherapy in the modern management of melanoma.

Avinash Gupta1,1, Fabio Gomes1,1, Paul Lorigan1,2,1,2.   

Abstract

The treatment of malignant melanoma has changed beyond recognition in the last 7 years. Where previously single agent dacarbazine was often the only treatment used for advanced disease, now there are potentially multiple lines of treatment, based on immunotherapy and targeted treatment options, either as monotherapy or in combination. In this brave new world the question arises, does chemotherapy still have any relevance in the modern management of melanoma? In this review, we summarize the various chemotherapeutic options that have been trialled in melanoma to date, and discuss the role chemotherapy may still play in treating melanoma, potentially in combination with more novel agents, or in certain subtypes of melanoma.

Entities:  

Keywords:  biochemotherapy; chemotherapy; cytotoxic; dacarbazine; melanoma; mucosal; uveal

Year:  2017        PMID: 30190915      PMCID: PMC6094602          DOI: 10.2217/mmt-2017-0003

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN: 2045-0885


  89 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

Authors:  A Gupta; S Love; A Schuh; M Shanyinde; J M Larkin; R Plummer; P D Nathan; S Danson; C H Ottensmeier; P Lorigan; L Collins; A Wise; R Asher; R Lisle; M R Middleton
Journal:  Ann Oncol       Date:  2014-02-24       Impact factor: 32.976

3.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

4.  Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma.

Authors:  A Y Bedikian; R C DeConti; R Conry; S Agarwala; N Papadopoulos; K B Kim; M Ernstoff
Journal:  Ann Oncol       Date:  2010-09-20       Impact factor: 32.976

5.  Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia.

Authors:  Jun Ho Yi; Seong Yoon Yi; Hye Ran Lee; Soon Il Lee; Do Hyoung Lim; Jung Han Kim; Keon Woo Park; Jeeyun Lee
Journal:  Melanoma Res       Date:  2011-06       Impact factor: 3.599

Review 6.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

Authors:  Thomas K Eigentler; Ulrich M Caroli; Peter Radny; Claus Garbe
Journal:  Lancet Oncol       Date:  2003-12       Impact factor: 41.316

7.  Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Authors:  S Leyvraz; S Piperno-Neumann; S Suciu; J F Baurain; M Zdzienicki; A Testori; E Marshall; M Scheulen; T Jouary; S Negrier; J B Vermorken; E Kaempgen; X Durando; D Schadendorf; R Karra Gurunath; U Keilholz
Journal:  Ann Oncol       Date:  2014-02-07       Impact factor: 32.976

8.  Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Authors:  M F Avril; S Aamdal; J J Grob; A Hauschild; P Mohr; J J Bonerandi; M Weichenthal; K Neuber; T Bieber; K Gilde; V Guillem Porta; J Fra; J Bonneterre; P Saïag; D Kamanabrou; H Pehamberger; J Sufliarsky; J L Gonzalez Larriba; A Scherrer; Y Menu
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

Review 9.  Treatment of metastatic melanoma: an overview.

Authors:  Shailender Bhatia; Scott S Tykodi; John A Thompson
Journal:  Oncology (Williston Park)       Date:  2009-05       Impact factor: 2.990

Review 10.  Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.

Authors:  J Doukas; A Rolland
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

View more
  7 in total

1.  Antiproliferative Copper(II) Complexes Bearing Mixed Chelating Ligands: Structural Characterization, ROS Scavenging, In Silico Studies, and Anti-Melanoma Activity.

Authors:  Rodica Olar; Catalin Maxim; Mihaela Badea; Mihaela Bacalum; Mina Raileanu; Speranta Avram; Nataša Čelan Korošin; Teodora Burlanescu; Arpad Mihai Rostas
Journal:  Pharmaceutics       Date:  2022-08-14       Impact factor: 6.525

Review 2.  Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.

Authors:  F Serra; S Barruscotti; T Dominioni; A Zuccarini; P Pedrazzoli; S Chiellino
Journal:  Curr Oncol Rep       Date:  2021-05-19       Impact factor: 5.075

Review 3.  Melanoma Management: From Epidemiology to Treatment and Latest Advances.

Authors:  Joana Lopes; Cecília M P Rodrigues; Maria Manuela Gaspar; Catarina Pinto Reis
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

4.  A twelve-gene signature for survival prediction in malignant melanoma patients.

Authors:  Le-Bin Song; Qi-Jie Zhang; Xiao-Yuan Hou; Yan-Yan Xiu; Lin Chen; Ning-Hong Song; Yan Lu
Journal:  Ann Transl Med       Date:  2020-03

5.  Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanoma.

Authors:  Cristiano Guttà; Arman Rahman; Claudia Aura; Peter Dynoodt; Emilie M Charles; Elodie Hirschenhahn; Jesuchristopher Joseph; Jasper Wouters; Ciaran de Chaumont; Mairin Rafferty; Madhuri Warren; Joost J van den Oord; William M Gallagher; Markus Rehm
Journal:  Cell Death Dis       Date:  2020-02-13       Impact factor: 8.469

6.  Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism.

Authors:  Iwona Karwaciak; Anna Sałkowska; Kaja Karaś; Jarosław Dastych; Marcin Ratajewski
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 7.  Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma.

Authors:  Siddhartha Sood; Rahul Jayachandiran; Siyaram Pandey
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.